Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

× No keyword cloud information.

107 in total

1. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study.

Authors: H Alexanderson; C H Stenström; I Lundberg
Journal: Rheumatology (Oxford) Date: 1999-07 Impact factor: 7.580

2. Pilot trial of etanercept in the treatment of inclusion-body myositis.

Authors: R J Barohn; L Herbelin; J T Kissel; W King; A L McVey; D S Saperstein; J R Mendell
Journal: Neurology Date: 2006-01-24 Impact factor: 9.910

3. A functional index in myositis.

Authors: A Josefson; E Romanus; J Carlsson
Journal: J Rheumatol Date: 1996-08 Impact factor: 4.666

4. Translating the science of quality of life into practice: What do dermatology life quality index scores mean?

Authors: Yan Hongbo; Charles L Thomas; Michael A Harrison; M Sam Salek; Andrew Y Finlay
Journal: J Invest Dermatol Date: 2005-10 Impact factor: 8.551

5. SLICC/ACR Damage Index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus.

Authors: T Stoll; B Seifert; D A Isenberg
Journal: Br J Rheumatol Date: 1996-03

6. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. The Juvenile Dermatomyositis Disease Activity Collaborative Study Group.

Authors: D J Lovell; C B Lindsley; R M Rennebohm; S H Ballinger; S L Bowyer; E H Giannini; J E Hicks; J E Levinson; R Mier; L M Pachman; M H Passo; M D Perez; A M Reed; K N Schikler; M Smith; L S Zemel; L G Rider
Journal: Arthritis Rheum Date: 1999-10

7. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life.

Authors: Jennifer L Hundley; Christie L Carroll; Wei Lang; Beverly Snively; Gil Yosipovitch; Steven R Feldman; Joseph L Jorizzo
Journal: J Am Acad Dermatol Date: 2005-12-02 Impact factor: 11.527

8. Functional outcome and quality of life in adult patients with idiopathic inflammatory myositis.

Authors: A Ponyi; G Borgulya; T Constantin; A Váncsa; L Gergely; K Dankó
Journal: Rheumatology (Oxford) Date: 2004-09-20 Impact factor: 7.580

9. Functional index-2: Validity and reliability of a disease-specific measure of impairment in patients with polymyositis and dermatomyositis.

Authors: Helene Alexanderson; Lisbet Broman; Anna Tollbäck; Annika Josefson; Ingrid E Lundberg; Christina H Stenström
Journal: Arthritis Rheum Date: 2006-02-15

10. The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II Study Group.

Authors:
Journal: Arch Neurol Date: 1996-02

112 in total

1. The olfactory function is impaired in patients with idiopathic inflammatory myopathies.

Authors: L Iaccarino; N Shoenfeld; M Rampudda; M Zen; M Gatto; A Ghirardello; N Bassi; L Punzi; Y Shoenfeld; A Doria
Journal: Immunol Res Date: 2014-12 Impact factor: 2.829

Review 2. Treatment of inflammatory myopathy: emerging therapies and therapeutic targets.

Authors: Siamak Moghadam-Kia; Rohit Aggarwal; Chester V Oddis
Journal: Expert Rev Clin Immunol Date: 2015-08-27 Impact factor: 4.473

3. Patient reported outcomes in GNE myopathy: incorporating a valid assessment of physical function in a rare disease.

Authors: Christina Slota; Margaret Bevans; Li Yang; Joseph Shrader; Galen Joe; Nuria Carrillo
Journal: Disabil Rehabil Date: 2017-02-07 Impact factor: 3.033

4. [Early symptoms of dermatomyositis and antisynthetase syndrome].

Authors: B Maurer
Journal: Z Rheumatol Date: 2013-12 Impact factor: 1.372

Review 5. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies.

Authors: Lisa G Rider; James D Katz; Olcay Y Jones
Journal: Rheum Dis Clin North Am Date: 2013-09-19 Impact factor: 2.670

6. Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.

Authors: Rebecca De Lorenzo; Iago Pinal-Fernandez; Wilson Huang; Jemima Albayda; Eleni Tiniakou; Cheilonda Johnson; Jose C Milisenda; Maria Casal-Dominguez; Andrea M Corse; Sonye K Danoff; Lisa Christopher-Stine; Julie J Paik; Andrew L Mammen
Journal: Neurology Date: 2018-05-04 Impact factor: 9.910